Literature DB >> 10408345

Expression of complement regulator proteins in primary and metastatic malignant melanoma.

M Weichenthal1, U Siemann, K Neuber, E W Breitbart.   

Abstract

The expression of complement regulatory antigens C3b/C4b receptor, (CD35) membrane cofactor protein (CD46), decay accelerating factor (CD55), and homologous restriction factor 20 (CD59) was determined immunohistochemically on ten primary malignant melanomas, 16 metastatic lesions, and ten melanocytic nevi. All of the melanocytic nevi and 9/10 primary melanomas showed both expression of CD46 and CD59. In one primary melanoma lacking CD46, expression of CD35 could be detected. In metastatic melanoma, 9/16 metastases were CD46+/CD59+, two were CD46-/CD59+, one CD46+/CD59-, and four CD46-/CD59-. Additionally, CD55 could be detected in two CD46+/CD59+ metastases, and CD35 in one. Expression or lack of complement regulatory antigens did not correlate with the expression of GD2, GD3, HMB-45 or S-100. In conclusion, some cases of metastatic melanoma show loss of normal expression of complement regulatory proteins. This might have implications on the immune response or the efficacy of immune therapy in malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408345     DOI: 10.1111/j.1600-0560.1999.tb01833.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  2 in total

1.  RNA interference characterization of proteins discovered by proteomic analysis of pancreatic cancer reveals function in cell growth and survival.

Authors:  Candy N Lee; Jenny L Heidbrink; Katherine McKinnon; Victoria Bushman; Henrik Olsen; William FitzHugh; Aiqun Li; Karen Van Orden; Tao He; Steven M Ruben; Paul A Moore
Journal:  Pancreas       Date:  2012-01       Impact factor: 3.327

2.  Bioinformatic analysis of the membrane cofactor protein CD46 and microRNA expression in hepatocellular carcinoma.

Authors:  Zejun Lu; Chuanfu Zhang; Jiajun Cui; Qi Song; Ligui Wang; Jingbo Kang; Peng Li; Xiaofeng Hu; Hongbin Song; Jinliang Yang; Yansong Sun
Journal:  Oncol Rep       Date:  2013-11-28       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.